非小细胞肺癌患者血浆外泌体APE1的表达与铂类化疗敏感性相关

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (2): 165-170.

非小细胞肺癌患者血浆外泌体APE1的表达与铂类化疗敏感性相关

赵晓龙¹, 代晓燕¹, 毛成毅², 肖华亮², 王东¹, 戴楠^1*

陆军军医大学大坪医院 1.肿瘤科; 2.病理科, 重庆 400042

收稿日期:2019-12-30 修回日期:2020-06-27 出版日期:2021-02-05 发布日期:2021-01-19
通讯作者: ^*85459236@qq.com
基金资助:
国家自然科学基金(81672312)

Plasma exosomal APE1 expression of NSCLC patients is related to the sensitivity of platinum chemotherapy

ZHAO Xiao-long¹, DAI Xiao-yan¹, MAO Cheng-yi², XIAO Hua-liang², WANG Dong¹, DAI Nan^1*

1. Department of Oncology;2. Department of Pathology, Daping Hospital, Army Medical University, Chongqing 400042, China

Received:2019-12-30 Revised:2020-06-27 Online:2021-02-05 Published:2021-01-19
Contact: ^*85459236@qq.com

摘要/Abstract

摘要： 目的研究血浆外泌体脱嘌呤脱嘧啶核酸内切酶(APE1)表达,以及外泌体APE1表达与非小细胞肺癌(NSCLC)铂类化疗敏感性的关系。方法选取2017年1月至2019年6月于大坪医院就诊的ⅢB或Ⅳ期无驱动基因突变的NSCLC患者136例,对血浆外泌体APE1进行提取和鉴定。采用Western blot和ELISA检测外泌体APE1表达,采用免疫组化检测组织APE1表达。根据实体肿瘤疗效评价标准,分为铂类化疗应答组和铂类化疗无应答组,观察APE1表达水平与患者治疗敏感性的关系。结果成功分离了血浆外泌体,并确定外泌体中的APE1是外周血中APE1存在的主要方式。与健康人相比,NSCLC患者外泌体APE1水平明显升高(P＜0.001)。与NSCLC组织低表达APE1的患者相比,组织APE1高表达的患者其血浆APE1水平明显升高(P＜0.01)。化疗无应答组的外泌体APE1水平明显高于化疗应答组(P＜0.001),化疗无应答组中外泌体APE1水平在化疗后较初始水平明显提高(P＜0.01),而化疗应答组则无明显变化。结论血浆外泌体APE1可作为评价患者对铂类化疗药物反应的敏感指标。

关键词: 非小细胞肺癌, 外泌体, APE1, 耐药

Abstract: Objective To study the expression of apurinic aprimidinic endonuclease 1 (APE1) and the relationship between the expression of APE1 and the sensitivity of platinum chemotherapy for NSCLC. Methods From January 2018 to June 2019, 136 NSCLC patients with stage Ⅲ B or Ⅳ plus non driving gene mutation were selected to extract and identify the plasma exosome APE1. Western blot and ELISA were used to detect the expression of APE1 in exosomes. Immunohistochemistry was used to detect the expression of APE1 in tissues. According to the response evaluation criteria in solid tumors, the patients were divided into two groups: the effective group and the ineffective group. The relationship between APE1 expression and drug sensitivity was examined. Results APE1 was mainly located within exosomes in peripheral blood. The level of APE1 in the exosomes of NSCLC patients was significantly higher than that of normal controls (P＜ 0.001). Compared with NSCLC patients with low tissue APE1 expression, patients with high tissue APE1 expression showed a significantly higher plasma APE1 level (P＜ 0.01). The APE1 level of exosomes in the chemotherapy ineffective group was significantly higher than that in the chemotherapy effective group (P＜ 0.001). Conclusions Exosomal APE1 can be used as a sensitive indicator to evaluate the response of patients to chemotherapy with platinum.

Key words: non small cell lung cancer, exosome, APE1, drug resistance

中图分类号:

R734.2

赵晓龙, 代晓燕, 毛成毅, 肖华亮, 王东, 戴楠. 非小细胞肺癌患者血浆外泌体APE1的表达与铂类化疗敏感性相关[J]. 基础医学与临床, 2021, 41(2): 165-170.

ZHAO Xiao-long, DAI Xiao-yan, MAO Cheng-yi, XIAO Hua-liang, WANG Dong, DAI Nan. Plasma exosomal APE1 expression of NSCLC patients is related to the sensitivity of platinum chemotherapy[J]. Basic & Clinical Medicine, 2021, 41(2): 165-170.

参考文献

[1] Wu X, Deng Y, Zu Y, et al. Histone demethylase KDM4C activates HIF1α/VEGFA signaling through the costimulatory factor STAT3 in NSCLC[J]. Am J Cancer Res, 2020, 10:491-506.
[2] Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC[J]. Nat Rev Cancer, 2017, 17:637-658.
[3] Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer[J]. Cancer Treat Rev, 2016, 44:42-50.
[4] 许文亚, 林子英, 李春艳, 等. APE1表达变化对人非小细胞肺癌细胞A549增殖的影响[J]. 现代肿瘤医学, 2016,24:3875-3880.
[5] Dai N, Cao XJ, Li MX, et al. Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer[J]. PLoS One, 2013, 8: e58001.doi: 10.1371/journal.pone.0058001.
[6] Pegtel DM, Gould SJ. Exosomes[J]. Annu Rev Biochem, 2019, 88:487-514.
[7] 丁雨钦, 吕喜英. ERCC1与非小细胞肺癌铂类耐药的研究进展[J]. 医学院学报, 2012, 29: 197-199.
[8] Basourakos SP, Li L, Aparicio AM, et al. Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions[J]. Curr Med Chem, 2017, 24:1586-1606.
[9] Simran K, Zubaidah MR, Marie CG, et al. CUX1 Stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide[J]. Euro Oncol, 2018, 20: 484-493.
[10] Wang D, Xiang DB, Yang XQ, et al. APE1 over-expression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells[J]. Lung Cancer, 2009, 66:298-304.
[11] Zhang S, He L, Dai N, et al. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients[J]. Oncotarget, 2016, 7: 77482-77494.
[12] Lu GS, Li M, Xu CX, et al. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma[J]. Cell Death Dis, 2018, 9:1111-1120.

[1]	赵霞, 徐薇薇, 刘益萌, 索智敏. 中国大陆地区幽门螺杆菌对常用抗生素耐药性的临床分析[J]. 基础医学与临床, 2022, 42(7): 1077-1082.
[2]	陈秋霞, 杨黎星, 马瑞, 赵永晶, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐抑制人胰腺癌吉西他滨耐药细胞株增殖及线粒体能量代谢[J]. 基础医学与临床, 2022, 42(4): 570-576.
[3]	何啸, 胡为杰, 吕文昌, 任玉萍, 吴敏, 吴毅平, 张奇. 环状RNA在乳腺癌中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 507-511.
[4]	李英杰, 杨庭楷, 纪志刚, 文进. 外泌体在前列腺癌诊疗中的研究进展[J]. 基础医学与临床, 2022, 42(1): 163-167.
[5]	姜学东李文雅. Erastin诱导人非小细胞肺癌细胞系A549凋亡[J]. 基础医学与临床, 2021, 41(9): 1313-1317.
[6]	万雪琼陈佳何超叶星明. 花姜酮通过上调FBXW7表达抑制人非小细胞肺癌细胞系A549增殖、迁移和侵袭[J]. 基础医学与临床, 2021, 41(8): 1163-1168.
[7]	杨汶川韩东杨帆. LINC00607抑制miR-372影响A549/DDP细胞的增殖和凋亡[J]. 基础医学与临床, 2021, 41(7): 1001-1006.
[8]	杨旭东于红亮李静赵春华. 巨噬细胞J774A.1外泌体促进结直肠癌细胞系MC38和CT26增殖和迁移[J]. 基础医学与临床, 2021, 41(6): 799-804.
[9]	任孟先梁伟刘艳. 塞来昔布联合IMRT对老年中晚期非小细胞肺癌患者免疫功能和血清肿瘤标志物的影响[J]. 基础医学与临床, 2021, 41(6): 890-894.
[10]	朱娟, 周英, 李颖佳. LncRNA SNHG7通过抑制miR-186增强人急性髓系白血病细胞耐药性[J]. 基础医学与临床, 2021, 41(2): 171-177.
[11]	朱萌张宁陶伟. 人胃癌细胞系AGS外泌体miR-106a对腹膜间皮细胞系HMrSV5表型的影响[J]. 基础医学与临床, 2021, 41(11): 1564-1569.
[12]	吴友明刘娜斯曹明月黄薇刘雁勇杨楠. Hsp90靶向抑制剂多肽P7与多西他赛联用对肺腺癌细胞系A549的协同抗肿瘤作用[J]. 基础医学与临床, 2020, 40(5): 639-643.
[13]	张新然张弋高慧儿强兆艳李咏梅. Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药[J]. 基础医学与临床, 2020, 40(4): 473-478.
[14]	孙慧霞郭哲许静. 沉默HOXB7抑制人宫颈癌细胞系CASKI转移与增强顺铂敏感性[J]. 基础医学与临床, 2020, 40(4): 532-537.
[15]	董保龙韩彩文史明郑文学杨晓军. 波形蛋白在肝细胞癌中的研究进展[J]. 基础医学与临床, 2020, 40(2): 238-242.